Fundus Autofluorescence: A Window Into Retinal Health
Understanding Fundus Autofluorescence
FAF imaging detects a substance called lipofuscin that naturally builds up in the retinal pigment epithelium (RPE). The RPE is a single layer of cells beneath the retina that supports your vision. Lipofuscin is a metabolic byproduct created when RPE cells break down and recycle the outer segments of photoreceptor cells. Photoreceptor cells are the light-sensing cells in your retina.
When a specific wavelength of blue light is directed at the retina, lipofuscin absorbs it and emits a yellow-green glow. The FAF camera captures this glow to create a detailed metabolic map of the back of the eye. Areas that glow brighter than normal suggest excess lipofuscin buildup or increased cellular stress. Areas that appear dark suggest that RPE cells are damaged, lost, or blocked from view.
FAF provides information that is different from standard retinal photographs, optical coherence tomography (OCT), or fluorescein angiography. While OCT shows the physical layers of the retina in cross-section, FAF reveals how actively those layers are metabolizing waste products. Standard retinal photos capture the visible surface of the retina, but FAF can detect abnormalities hidden beneath the surface.
This unique ability makes FAF valuable for identifying early disease changes before they become visible during a routine eye exam. A retina specialist may use FAF alongside other imaging tests to build a complete picture of retinal health.
Several types of FAF imaging platforms are available in clinical practice. Each offers specific advantages depending on the condition being evaluated.
- Confocal scanning laser ophthalmoscope (cSLO): Produces high-contrast images by filtering out scattered light, making it the most commonly used FAF platform.
- Fundus camera-based FAF: Uses a modified fundus camera and is widely available in many clinical settings.
- Ultra-widefield FAF: Captures a much larger view of the retina, including the far periphery, to detect changes that standard imaging may miss.
- Near-infrared autofluorescence (NIR-AF): Uses a longer wavelength of light (790 nm) that can image through cataracts and other lens changes more effectively.
Who Benefits From FAF Imaging
FAF plays a central role in evaluating age-related macular degeneration (AMD), the leading cause of vision loss in adults over 50 in the United States. In early AMD, peripheral autofluorescent abnormalities were found in 64 percent of AMD eyes compared to 36 percent of control eyes (AAO EyeNet). Abnormal peripheral FAF patterns were also found in 51.5 percent of wet AMD eyes compared with 18.8 percent of control eyes (Ophthalmic Research, Clinical Ophthalmology).
For patients with geographic atrophy, an advanced form of dry AMD, FAF is particularly useful for tracking how quickly areas of RPE cell loss are expanding. Specific patterns of bright autofluorescence surrounding areas of atrophy can help a retina specialist predict how rapidly the condition may progress.
FAF imaging is a key diagnostic tool for inherited retinal conditions such as Stargardt disease, retinitis pigmentosa, and choroideremia. In Stargardt disease, FAF reveals a characteristic pattern of dark flecks surrounded by areas of increased brightness. In retinitis pigmentosa, a ring of bright autofluorescence often marks the boundary between functioning and damaged retina. As the disease progresses, this ring typically shrinks inward.
FAF can also help differentiate between various inherited conditions that may look similar during a standard eye exam. Genetic testing combined with FAF findings often leads to a more accurate diagnosis.
Some medications can cause toxicity to the retina, and FAF is one of the earliest ways to detect this damage. Hydroxychloroquine, a drug commonly used for lupus and rheumatoid arthritis, can cause a distinctive ring pattern on FAF imaging. This pattern signals early toxicity to the RPE cells near the center of the macula. Pentosan polysulfate sodium, used for bladder conditions, has also been associated with characteristic FAF changes.
Guidelines recommend regular retinal screening for patients taking hydroxychloroquine, especially at higher doses. FAF imaging can detect changes before vision loss occurs. This allows the prescribing doctor and retina specialist to adjust treatment.
People with high myopia (severe nearsightedness) may show unique FAF patterns. The prevalence of radial FAF was 0.78 percent in highly myopic women, and these patients may carry mutations in RPGR or RP2 genes (PubMed, 2023). FAF can help identify whether myopic retinal changes are degenerative or related to an underlying inherited condition.
Signs and Symptoms That May Prompt FAF Testing
A retina specialist may recommend FAF imaging when a patient reports certain visual symptoms. These include gradual central vision loss, difficulty reading or recognizing faces, distortion of straight lines, or a growing blind spot. Some patients notice that colors appear faded or washed out. This can indicate changes in the RPE layer that FAF is designed to detect.
Not all patients with abnormal FAF findings have symptoms. In many cases, FAF reveals early disease before the patient notices any vision changes at all.
An optometrist or ophthalmologist may refer a patient for FAF imaging after noticing drusen (yellow deposits under the retina), pigment changes in the macula, or other retinal abnormalities during a routine dilated eye exam. These findings may suggest an underlying condition that FAF can help characterize more precisely.
Patients already diagnosed with a retinal condition may undergo FAF imaging at regular intervals to track disease progression. For geographic atrophy in dry AMD, FAF is considered one of the best tools for measuring the rate of RPE cell loss over time. For inherited retinal diseases, repeated FAF imaging can show whether the area of functioning retina is stable or shrinking.
How the FAF Test Is Performed
FAF imaging requires pupil dilation in most cases. A technician will place dilating drops in the eyes, which take about 20 to 30 minutes to take full effect. Patients should plan for blurred vision and light sensitivity for several hours after dilation. Bringing sunglasses and arranging a ride home is recommended.
No special fasting or medication changes are needed before the test. Patients should inform the technician about any eye conditions, cataracts, or allergies to dilating drops.
The patient sits in front of the imaging device and rests the chin and forehead on a support frame. The technician adjusts the camera and asks the patient to look at a small fixation target. A series of images are captured while a blue or near-infrared light illuminates the retina. The process is painless and does not involve any contact with the eye.
Modern FAF systems use real-time image averaging, which combines multiple frames to produce a clearer final image. The entire imaging session typically takes five to ten minutes per eye.
There is no recovery time needed from the imaging itself. The dilation drops may cause blurry near vision and light sensitivity for three to six hours. A retina specialist will review the images and discuss the findings, sometimes during the same visit or at a follow-up appointment.
Understanding FAF Results
In a healthy eye, FAF shows a relatively uniform glow across the back of the retina with a few predictable variations. The optic nerve head appears dark because it lacks RPE cells. The fovea, the very center of the macula, appears slightly darker due to macular pigment that blocks some of the fluorescent signal. Blood vessels also appear dark because blood absorbs the excitation light.
A mild, even increase in autofluorescence is normal with aging as lipofuscin gradually accumulates in RPE cells over decades.
Areas that appear brighter than normal on FAF are called hyperautofluorescent. This increased signal can indicate several things.
- Excess lipofuscin accumulation, often seen in Stargardt disease and early AMD.
- RPE cells under metabolic stress, which may precede cell death.
- Active inflammation affecting the RPE layer.
- Fluid beneath the retina that concentrates fluorescent material.
Dark areas on FAF are called hypoautofluorescent. These typically indicate more advanced damage.
- RPE cell death or atrophy, as seen in geographic atrophy.
- Blockage of the fluorescent signal by blood, pigment, or scar tissue.
- Severe photoreceptor and RPE loss in late-stage inherited retinal diseases.
- Areas previously treated with laser photocoagulation (thermal laser treatment).
Conditions Commonly Evaluated With FAF
FAF imaging is particularly important for identifying geographic atrophy (GA) and measuring its growth over time in patients with advanced dry AMD. Specific FAF patterns surrounding areas of atrophy, such as banded, diffuse, or patchy increased autofluorescence, have been shown to predict how quickly atrophy will expand. This information helps guide decisions about treatments such as Syfovre (pegcetacoplan), a complement inhibitor, and Izervay (avacincaptad pegol), a C5 complement inhibitor, which are approved to slow the growth of geographic atrophy.
In wet AMD, which is a distinct condition from dry AMD and requires different treatment, FAF can reveal peripheral retinal changes and RPE damage that may not be visible on OCT alone. This additional information can influence monitoring schedules for patients receiving anti-VEGF injections such as Eylea (aflibercept), Lucentis (ranibizumab), or Vabysmo (faricimab). These anti-VEGF medications treat the abnormal blood vessel growth in wet AMD, which is a separate disease process from the RPE atrophy seen in dry AMD. It is important to note that anti-VEGF injections are used specifically for wet AMD and are not a treatment for dry AMD.
Stargardt disease is the most common inherited macular dystrophy. It is caused by mutations in the ABCA4 gene that lead to abnormal lipofuscin buildup. FAF is considered the gold standard imaging test for this condition. It clearly shows the characteristic pattern of bright flecks and central dark areas of atrophy. Serial FAF imaging helps track disease progression over months and years.
In retinitis pigmentosa, FAF typically shows a ring of increased autofluorescence. This ring corresponds to the junction between functioning and damaged retina. The size of this ring has been correlated with the remaining visual field. As the ring contracts over time, peripheral vision continues to narrow. FAF monitoring helps retina specialists assess the rate of progression.
For patients on long-term hydroxychloroquine therapy, FAF can detect a characteristic pericentral or parafoveal ring of increased autofluorescence that indicates early toxicity. This finding may appear before damage is detectable on visual field testing or OCT. Early detection allows the prescribing physician to consider stopping or reducing the medication before irreversible vision loss occurs.
Recent Advances in FAF Technology
Quantitative FAF (qFAF) is an emerging technology that assigns numerical values to autofluorescence intensity. Traditional FAF images are qualitative. They show relative patterns of brightness and darkness but cannot be precisely compared between patients or across visits. Quantitative FAF uses an internal reference standard to produce objective measurements. This advance allows retina specialists to track subtle changes in lipofuscin levels over time.
Researchers are developing artificial intelligence (AI) and deep learning models to analyze FAF images automatically. These tools may eventually help screen large populations for early retinal disease. They could also assist retina specialists in identifying progression patterns that are difficult to detect visually.
Ultra-widefield FAF now captures images showing far more of the peripheral retina than standard devices. This expanded view has revealed that many retinal diseases affect the periphery earlier or more extensively than previously recognized. Red light autofluorescence, using wavelengths between 642 and 705 nm, provides improved visualization of the fovea by avoiding absorption from macular pigment. This newer technique offers additional diagnostic information in conditions affecting the very center of the macula.
When to See a Retina Specialist
Certain symptoms require urgent attention from a retina specialist or an emergency room visit. Sudden increases in floaters, flashes of light, a shadow or curtain across the vision, or sudden vision loss in one eye are symptoms that demand immediate care. These symptoms can signal retinal emergencies such as retinal detachment. While they may not be related to conditions diagnosed by FAF, they require same-day evaluation to protect your vision.
Patients with known risk factors for abnormal FAF findings should discuss appropriate screening schedules with a retina specialist. Risk factors include a family history of inherited retinal disease, a diagnosis of AMD, long-term use of hydroxychloroquine or pentosan polysulfate sodium, high myopia, and advancing age. Baseline FAF imaging followed by regular monitoring can detect early changes before symptoms develop.
Questions and Answers
FAF imaging is a safe, non-invasive test. It does not involve any injections, dyes, or contact with the eye. The low-intensity light used during the test does not damage the retina. The only discomfort comes from the dilating drops used to widen the pupil, which can cause temporary blurry vision and light sensitivity lasting several hours.
Fluorescein angiography requires an injection of fluorescein dye into a vein in the arm. The dye travels through the bloodstream and highlights blood vessels in the retina. FAF does not require any dye injection. Instead, it captures the natural fluorescence of lipofuscin already present in the RPE cells. The two tests provide different but complementary information. A retina specialist may order both tests depending on the clinical situation.
The frequency of FAF imaging depends on the condition being monitored. Patients with geographic atrophy may have FAF imaging every six to twelve months to measure the rate of atrophy expansion. Patients taking hydroxychloroquine may have annual FAF screening after an initial baseline. For inherited retinal diseases, imaging intervals vary based on how quickly the condition is progressing. A retina specialist will recommend a schedule tailored to each patient's specific needs.
Yes. One of the most valuable aspects of FAF is its ability to reveal metabolic changes in the RPE before those changes cause noticeable symptoms. In conditions such as hydroxychloroquine toxicity, early AMD, and inherited retinal diseases, FAF can show abnormal patterns months or years before vision loss begins. This early detection gives retina specialists and patients more time to plan appropriate monitoring or treatment strategies.
Some general ophthalmologists and optometrists have FAF-capable imaging equipment and may perform the test as part of a screening exam. However, interpreting complex FAF patterns and making treatment decisions based on the findings typically requires the expertise of a retina specialist. If your eye care provider identifies concerning findings on FAF, a referral to a retina specialist is the appropriate next step for further evaluation and management.